Methotrexate has no role in the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction or coronary artery disease. Results from the Cardiovascular Inflammation Reduction Trial (CIRT) of low-dose methotrexate versus placebo in almost 5,000 patients found no impact on laboratory measures of inflammation or clinical end points. Patients also had ...
Ischaemic heart disease
Arthritis drug fails in inflammation in CVD
By Mardi Chapman
15 Nov 2018